Vigil Neuro
Kelley C. Larson possesses extensive experience in the field of discovery biology and pharmacology, currently serving as Senior Director at Vigil Neuroscience since November 2020, following previous roles as Director and Principal Scientist within the organization. Prior to Vigil Neuroscience, Kelley held the position of Principal Investigator at Cyclerion and Principal Scientist at Tiaki Therapeutics. Earlier career contributions included consulting for the Dementia Discovery Fund and serving as Staff Scientist II at Yumanity Therapeutics. Kelley's academic credentials include a Master’s degree in Biology and Biotechnology from Harvard University and a Bachelor’s degree in Biology and Chemistry from UMass Boston.
This person is not in any offices
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.